Key statistics
On Friday, Vera Therapeutics Inc (VERA:NMQ) closed at 48.09, -5.30% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 48.29 |
---|---|
High | 48.88 |
Low | 47.10 |
Bid | 35.00 |
Offer | 50.45 |
Previous close | 49.04 |
Average volume | 1.63m |
---|---|
Shares outstanding | 61.96m |
Free float | 56.33m |
P/E (TTM) | -- |
Market cap | 2.98bn USD |
EPS (TTM) | -2.20 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Vera Therapeutics to Participate at Upcoming Investor Conferences
- Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
- Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
- Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
- Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
- Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
- Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
More ▼